Biotechnologies

Therapure Biopharma Inc. and LFB Biotechnologies Announce Development Services Contract for New Therapeutic Protein

Therapure will apply its expertise to the development of an innovative plasma protein resulting from LFB's research Toronto, Canada and Les Ulis, France (PRWEB) March 6, 2009 -- Thomas Wellner, President and CEO of Therapure BioPharma Inc. and Christian Béchon, P...

Millennium Biotechnologies Reports Strong Third Quarter Revenue and Financial Results

BASKING RIDGE, N.J., Dec. 15 /PRNewswire-FirstCall/ -- Millennium Biotechnologies Group, Inc. (OTC Bulletin Board: MBTG) a leader in the development of targeted products in the Clinical and Sports Nutrition Market, announces financial results for the third quarter ended September 30, 2008. ...

Ezra Van Gelder Joins Microchip Biotechnologies as Executive Vice President R&D

DUBLIN, Calif., Dec. 4 /PRNewswire/ -- Microchip Biotechnologies, a private company developing the Apollo next-generation fluidics platform for Life Sciences, announced today that Ezra Van Gelder has joined its team as Executive Vice President of R&D. Ezra Van Gelder brings Microchip ...

Veteran of the Beverage Industry, Ken Sadowsky, Joins Millennium Biotechnologies Board of Directors

BASKING RIDGE, N.J., Sept. 17 /PRNewswire-FirstCall/ -- Millennium Biotechnologies Group, Inc. (OTC Bulletin Board: MBTG) today announced that veteran beverage industry expert, Ken Sadowsky, has joined the Board of Directors. Mr. Sadowsky is currently the Executive Director of NIDA, an assoc...

Millennium Biotechnologies Inc. Signs Five Year $20,000,000 Purchase Agreement with Provider Services Inc. of Cleveland, Ohio

Product Shipments Begin November 15th, 2007 BASKING RIDGE, N.J., Nov. 13 /PRNewswire-FirstCall/ -- Millennium Biotechnologies Inc., wholly-owned subsidiary of Millennium Biotechnologies Group, Inc. (OTC Bulletin Board: MBTG), today announced that it had entered into a five-year $...

VaxGen and Raven biotechnologies Announce Signing of Definitive Merger Agreement

- Conference Call Scheduled for Tuesday, November 13, 8:00 EST - SOUTH SAN FRANCISCO, Calif., Nov. 12 /PRNewswire-FirstCall/ -- VaxGen Inc. (Pink Sheets: VXGN), a biopharmaceutical company, and Raven biotechnologies, inc., a privately held company focused on the development of monoclonal a...

MDS Analytical Technologies Acquires Blueshift Biotechnologies

Complementary technology to augment MDS Analytical Technologies' cellular analysis capabilities SUNNYVALE, CA, June 27 /PRNewswire-FirstCall/ - MDS Analytical Technologies, a leader in innovative solutions for drug discovery and life sciences research, today announced it...

TriLink BioTechnologies, Inc. Announces Sales and License Agreement With Glen Research Corporation for CleanAmp(TM) Amidites

... SAN DIEGO, June 24 /PRNewswire/ -- TriLink biotechnologies (TriLink), announced that it has signed a sales and license agreement with Glen Research Corporation to sell TriLink's CleanAmp(TM) Amidites. Glen Res...

Clinical Studies Validate Cancer Gene Delivery Platform: Landmark Publication Confirms Rexin-G Effectively Targets Metastatic Cancers and Improves Patient Survival

...SAN MARINO, Calif., June 22 /PRNewswire/ -- Epeius biotechnologies ( www.epeiusbiotech.com ) stuns the medical and ...n terms of evaluating efficacy. About Epeius biotechnologies Rexin-G is commercially available for the treat...for pancreatic cancer in the United States. Epeius biotechnologies Corporation is a privately held biopharmaceutical ...

Epeius Biotechnologies' Rexin-G Receives FDA Fast Track Designation for the Treatment of Pancreatic Cancer

...SAN MARINO, Calif., June 17 /PRNewswire/ -- Epeius biotechnologies ( www.epeiusbiotech.com ) announced today that i...cols for future medical praxis. About Epeius biotechnologies Epeius biotechnologies Corporation is a privately held biopharmaceutical ...

Biotechnologies in Medical Technology

Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation

STOCKHOLM, October 2 /PRNewswire/ -- Athera Biotechnologies AB and Dyax Corp. (NASDAQ: DYAX ) announced today that they have entered into a collaboration to discover and to develop therapeutic products for the prevention or treatment of cardiovascular inflammatory diseases. The collaboration...

Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine

SAN MARINO, Calif., Dec. 18 /PRNewswire/ -- Epeius Biotechnologies Corporation announced today their appreciation of the accomplishments of their contemporaries in 2007, a truly remarkable year in terms of biomedical research, scholarship, and gonzo journalism. It was a year in which a definit...

ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer

SAN MARINO, Calif., Dec. 18 /PRNewswire/ -- Epeius Biotechnologies Corporation announced today that the company has received a Certificate of Product Registration for Rexin-G(R) from the Philippine Bureau of Food and Drugs (BFAD), enabling the commercialization of its lead product as a safe an...

Gemin X Biotechnologies Announces Publication in Blood of Positive Preclinical Data of Lead Compound in Mantle Cell Lymphoma

MONTREAL--(BUSINESS WIRE)--May 15, 2007 - Gemin X Biotechnologies Inc. announced today that a report published in the journal Blood demonstrated that its lead compound, obatoclax (GX15-070), induced cell death in vitro in Mantle Cell Lymphoma (MCL) cell lines and primary cells from 11 MCL patients....

ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting

MONTREAL, June 19 /CNW/ - ConjuChem Biotechnologies (TSX:CJB) today announced that data relating to its proprietary PC-DAC(TM):Exendin-4 Albumin Conjugate for the treatment of Type 2 diabetes will be presented at the 67th Scientific Sessions of the American Diabetes Association (ADA) to be held ...

Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue Sarcoma and Osteosarcoma: Phase I/II & Confirmatory Phase II Studies

...stant metastatic soft tissue sarcoma and osteosarcoma. About Epeius biotechnologies Epeius biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the ...

TriLink Awarded a Phase II Grant for a Second Hot Start PCR Project

... SAN DIEGO, May 6 /PRNewswire/ -- TriLink biotechnologies (TriLink), a leading provider of custom nucleic acid-based compounds, has been awarded a Phase II Small Business Innovation Research (SBIR) grant of a...

Interim Analysis of Phase I/II Study of Rexin-G Confirms Efficacy With No Dose Limiting Toxicity in Metastatic Pancreatic Cancer

...lerated approval of Rexin-G for the treatment of all solid tumors that are resistant to standard chemotherapy. About Epeius Biotechnologies Epeius biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization ...

Immunosyn Announces Biozyme Lab's Receipt of MHRA Manufacturing License Approval in Europe for the Biopharmaceutical SF-1019

...O of Immunosyn. "Under the terms of our exclusive license agreement, Argyll biotechnologies is responsible for all regulatory approvals and clinical trials including t...se approval. Following a series of manufacturing "scale-up" studies, Argyll biotechnologies entered into an agreement with Biozyme Laboratories Limited to manufacture ...

Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine

...ets consumer products and manufactures quality products for other companies. Manufacturing operations comply with cGMP standards. Carrington's DelSite biotechnologies subsidiary is developing its proprietary GelSite(R) technology designed to provide controlled release of peptide and protein-based drugs. Carrington's...

Biotechnologies in Biological News

Marine microbes creating green waves in industry

...both the pharmaceutical and agrochemical industries." Commenting on the findings, BBSRC Chief Executive Professor Doug Kell, said: "Green and White biotechnologies are going to be an increasingly important part of the manufacturing landscape. Looking to biological systems that have been finely tuned by evolution ...

DNA barcoding of mosquito species deployed in bid to end elephantiasis

... New biotechnologies that allow scientists to quickly and accurately distinguish species based on a simple DNA analysis are being creatively deployed for the first time in...

KINAXOs Cellular Target Profiling reveals mTOR as a new target of Celebrex

...any, April 29, 2009 / b3c newswire / - Kinaxo biotechnologies GmbH has successfully applied its Cellular Target ...ebsite at www.kinaxo.com . About KINAXO Kinaxo biotechnologies GmbH is a privately-held biotechnology company bas...ead of Technology and Business Development KINAXO biotechnologies GmbH Am Klopferspitz 19a 82152 Martinsried, Germ...

Milestone achieved toward production of malaria treatment using synthetic biology and fermentation

... EMERYVILLE, Calif., March 2, 2009 - Amyris biotechnologies has announced the publication of an article which reveals the achievement of a significant milestone toward the production of amorphadiene, a precurso...

Reduction in parasite infections ahead for India

... at Queen's has been invited to Alagappa University in Tamil Nadu in southern India to share its expertise at the International Colloquium on Emerging biotechnologies in Agriculture, Animal Health and Productivity which runs from today until Friday. Dr Brennan has collaborated with Indian universities, including ...

Research yields pricey chemicals from biodiesel waste

... a platform for the 'green' production of a whole range of high-value products." Technologies based on Gonzalez's work have been licensed to Glycos biotechnologies Inc., a Houston-based startup company that plans to open its first demonstration facility within the next 12 months. ...

'Telepathic' genes recognize similarities in each other

...eimers, as well as contributing to ageing. Understanding this mechanism is also essential for refining precise artificial recombination techniques for biotechnologies and gene therapies of the future. The team is now working on a set of further experiments to determine exactly how these interactions work, includ...

2 federal public health grants awarded to Weill Cornell Medical College

...e Foundation Grant (NSF) for innovative research examining the ways in which the concept of human dignity is used in current debates about contentious biotechnologies such as embryonic stem cell research, human genetic enhancement and the creation of human-nonhuman chimeras. It will provide the first systematic asse...

New research could help us deliver genes for new bone formation

...ents needing orthopaedic procedures that require new bone. Professor Oreffo added "It is important that we explore the potential of new methods and biotechnologies to help meet the healthcare needs of an ageing population. Although research such as this is currently a number of years from being available to patie...

Could microbes solve Russia's chemical weapons conundrum?

...hem for growth. The group hopes that the bacterial strain can be used in the context of plant-microbial associa-tions to create a new generation of biotechnologies for remediation of soils contaminated by CWAs or products of their detoxification. "Bioutilization of organic compounds of reaction masses is a bio...

Biotechnologies in Biological Technology

Commonwealth Biotechnologies Presents Data at Forensic Sciences Meeting Confirming Benefits of ZyGEM's DNA Extraction Technology

- Data from Collaboration Applying forensicgem(TM) Technology to CBI's DNA Forensic Operations Presented at American Academy of Forensic Sciences Annual Meeting - - Shows ZyGEM's forensicGEM(TM) DNA Extraction Kits Increase DNA Yield, Simplify Workflow and Minimize Potential for Contam...

Beginners Luck, or Creative Artists of the First Rank? Epeius Biotechnologies Launches Rexin-G eBook Tutorial

SAN MARINO, Calif., Feb. 12 /PRNewswire/ -- Epeius Biotechnologies announces the launch of its new informative website, containing an award-winning video and an interactive e-book designed to introduce the general public to the tumor-targeting and cancer-destroying biotechnologies behind the clini...

Richter-Helm and Athera Biotechnologies Partner in Development of Recombinant Protein to Treat Cardiovascular Disease

HAMBURG, Germany and STOCKHOLM, January 21 /PRNewswire/ -- Richter-Helm BioLogics GmbH & Co. KG and Athera Biotechnologies AB have signed an agreement for the development and manufacturing of Athera's novel product for prevention of plaque rupture and athero-thrombosis through binding of t...

Benjamin Custodio Joins Millennium Biotechnologies to Expand International Sales

BASKING RIDGE, N.J., Oct. 28 /PRNewswire-FirstCall/ -- Millennium Biotechnologies Group, Inc. (OTC Bulletin Board: MBTG) today announced that Benjamin Custodio has joined the Company as Executive Vice President of International Sales and a member of the Board of Directors. Mr. Custodio has ove...

Millennium Biotechnologies Announces an Increased Annualized Purchase Commitment Totaling $5.8M from Provider Services, Inc.

Amended Master Purchase Contract Provides for the Sale of Ready to Drink Suite of Nutritional Supplements to Provider Services, Inc. to be Increased Annually by $3.4M or 142% BASKING RIDGE, N.J., June 5 /PRNewswire/ -- Millennium Biotechnologies Inc., wholly owned subsidi...

Canadian Centre for DNA Barcoding to Participate in Microchip Biotechnologies Early Access Program for Microchip-Based DNA Sample Preparation and Cycle Sequencing

DUBLIN, Calif., April 8, 2008 /PRNewswire/ -- Microchip Biotechnologies, Inc. (MBI) is pleased to announce that the Canadian Centre for DNA Barcoding (CCDB), at the Biodiversity Institute of Ontario, University of Guelph, will be the first participant to join MBI's early access program for the...

Raven biotechnologies Announces Collaboration With Monogram Biosciences to Advance Diagnostic Cancer Technologies

SOUTH SAN FRANCISCO, Calif., April 8, 2008 /PRNewswire/ -- Raven biotechnologies, inc., a privately held company focused on the discovery and development of monoclonal antibody therapeutics (MAbs) for cancer announced today that it has entered into an agreement with Monogram Biosciences, Inc.,...

Raven biotechnologies and Bioprocessing Technology Institute Announce Collaboration to Advance Discovery of Stem Cell Antibodies

SOUTH SAN FRANCISCO, Calif., and SINGAPORE, April 4, 2008 /PRNewswire/ -- Raven biotechnologies, inc., a privately held company focused on the discovery and development of monoclonal antibody therapeutics (MAbs) for cancer, and the Bioprocessing Technology Institute (BTI), today announced a co...

Epeius Biotechnologies Awarded U.S. Patent for Targeted Injectable Gene Delivery In Vivo

SAN MARINO, Calif., March 25 /PRNewswire/ -- Epeius Biotechnologies Corporation announced today the issue of U.S. Patent No. 7,347,998 for Targeted Gene Delivery in vivo. This patent provides additional intellectual property protection for the platform of highly advanced biotechnologies embodi...

Raven biotechnologies to Provide Updates on Oncology Pipeline With Four AACR Presentations

- Lead Clinical Program and Two Clinical Candidates Featured - SOUTH SAN FRANCISCO, Calif., Feb. 12 /PRNewswire/ -- Raven biotechnologies, inc., a privately held company focused on the discovery and development of monoclonal antibody therapeutics (MAbs) for cancer, announced four abstract...

Biotechnologies in Biological Products

Proteinase K from EPICENTRE Biotechnologies

Description: Component in MasterPure™ Purification Kits...
Company:EPICENTRE Biotechnologies

TE Buffer from EPICENTRE Biotechnologies

Description: Component in MasterPure™ Purification Kits...
Company:EPICENTRE Biotechnologies

MasterAmp 2X PCR PreMix F without (NH4)2SO4 from EPICENTRE Biotechnologies

Description: Sold individually or included in the MasterAmp™ PCR Optimization Kit without ammonium sulfate. Includes dNTPs, buffer, and varying amounts of MgCl2 and the MasterAmp™ PCR Enhancer (with betaine)....
Company:EPICENTRE Biotechnologies

MasterAmp Taq PCR Core Kit from EPICENTRE Biotechnologies

Description: Complete PCR kit. Includes: MasterAmp™ Taq DNA Polymerase, 10X PCR Buffer, MasterAmp™ 10X PCR Enhancer, dNTP Mix, 2.5 mM each, 25 mM MgCl2, Enzyme Dilution Buffer, Control Template and Primers Mix...
Company:EPICENTRE Biotechnologies

FailSafe PROBES Real-Time PCR Optimization Kit from EPICENTRE Biotechnologies

Description: The FailSafe™ PROBES Real-Time PCR System enables rapid, precise optimization of PCR experiments in which the product is detected using fluorescent target-specific labeled probes....
Company:EPICENTRE Biotechnologies

MasterPure Plant Leaf DNA Purification Kit from EPICENTRE Biotechnologies

Description: The MasterPure™ Plant Leaf DNA Purification Kit is designed for isolating DNA from 35-100 mg of fresh plant leaf tissue. The protocol can be completed in less than one hour and may be scaled up to obtain larger amounts of DNA. The purified DNA can be used for PCR amplification, restriction dig...
Company:EPICENTRE Biotechnologies

TE Buffer from EPICENTRE Biotechnologies

Description: ...
Company:EPICENTRE Biotechnologies

DNA Fragment 2X Precipitation Solution from EPICENTRE Biotechnologies

Description: Enables rapid purification of double-stranded DNA fragments = 200 bp, including, for example, PCR reaction products, DNA fragments obtained in restriction enzyme digests, or double-stranded cDNA...
Company:EPICENTRE Biotechnologies

RNase III, E. coli from EPICENTRE Biotechnologies

Description: Ribonuclease III (RNase III) from E. coli is an endoribonuclease that specifically digests double-stranded RNA (dsRNA) to dsRNA fragments that have 2-base, 3'-overhangs. Complete digestion of dsRNA results in dsRNA fragments of 12-15 bp. RNase III can digest double-stranded RNA composed of canoni...
Company:EPICENTRE Biotechnologies

GELase 50X Reaction Buffer from EPICENTRE Biotechnologies

Description: Component of GELase™ Agarose Gel-Digesting Preparation. 1 ml of 50X Buffer is sufficient for replacing the buffer in at least 5 g of gel....
Company:EPICENTRE Biotechnologies

More>>